Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Germany
(1,798/week)
Poland
(1,404/week)
France
(1,170/week)
Spain
(641/week)
Italy
(357/week)
View all
(9,157/week)
News
United States
(561/week)
Manufacturing
(389/week)
Energy
(293/week)
Technology
(380/week)
Other Manufacturing
(333/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Protein-bound paclitaxel
Jan 10, 2020
BW Therapeutics Announces Opening Of Series A Round And Strategic Partnering Initiatives
Nov 21, 2019
Catalent to Supply BeiGene's BTK Inhibitor BRUKINSA(TM) (zanubrutinib)
Sep 27, 2019
Health Canada approves Tecentriq® in combination with chemotherapy (nab-paclitaxel) as first immunotherapy treatment for aggressive form of breast cancer(1)
Jul 01, 2019
Boston Biomedical, Inc. Announces Update on Phase 3 CanStem111P Study of Napabucasin in Patients with Metastatic Pancreatic Cancer Following Interim Analysis
Feb 04, 2019
BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
Jan 18, 2019
AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer
Aug 09, 2018
BeiGene Initiates New Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab Combined with Chemotherapy as First-line Treatment for Patients with Advanced Squamous Non-Small Cell Lung Cancer in China
Jun 25, 2018
Merrimack Announces Top-Line Results from Randomized Phase 2 Trial of MM-141 in Front-Line Metastatic Pancreatic Cancer
Jun 01, 2018
Boston Biomedical, Inc. Highlights Presentations on Investigational Agents Napabucasin and DSP-7888 (ombipepimut-S*) at ASCO 2018
May 17, 2018
Boston Biomedical, Inc. Announces Presentations for Investigational Agents Napabucasin and DSP-7888 (ombipepimut-S*) to be Featured at ASCO 2018
Apr 20, 2018
Global $200 Billion Opportunity for Nanoparticle Drug Delivery Market by 2024 - Size, Current Trends, and Dynamics
Dec 20, 2017
MabVax Therapeutics Announces Completion of Enrollment and Initial Patient Dosing in an Expanded Cohort of the Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy
Jun 28, 2017
Halozyme Phase 2 Data In Advanced Pancreas Cancer Presented At European Society For Medical Oncology Symposium
Jun 04, 2017
Halozyme Phase 2 Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO
Jun 03, 2017
Boston Biomedical Presents Data Suggesting Anti-Cancer Activity of Investigational Stemness Inhibitor Napabucasin in Seven Tumor Types at ASCO 2017
Latest News
Feb 7, 2023
HOUSTEX 2023 Speakers Provide Real-World Solutions to Manufacturing Technology Adoption and Business Practices
Feb 7, 2023
HighGround Strengthens Its Florida Footprint With The Acquisition of Expert Water Removal
Feb 7, 2023
ESAB Corporation Schedules Fourth Quarter 2022 Earnings Release and Conference Call
Feb 7, 2023
Nodal Exchange achieves January trading records in power and environmental markets
Feb 7, 2023
Gallium Semiconductor Unveils Cutting-Edge Manufacturing Facility in the Philippines
Feb 7, 2023
Grupo Saesa and Trilliant Sign Strategic, Long-Term Partnership
Feb 7, 2023
Tachyum Unveils Air Defense Superiority Using Prodigy AI White Paper
Feb 7, 2023
Pluglink Signs KRW 15 billion EV Charger Assets Investment Agreement with KDB KIAMCO
View all News